Onconetix Statistics
Total Valuation
Onconetix has a market cap or net worth of $4.02 million. The enterprise value is $3.35 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Onconetix has 1.56 million shares outstanding.
| Current Share Class | 1.56M |
| Shares Outstanding | 1.56M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +150.88% |
| Owned by Insiders (%) | 1.14% |
| Owned by Institutions (%) | 6.31% |
| Float | 1.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.20 |
| Forward PS | n/a |
| PB Ratio | 1.19 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.08, with a Debt / Equity ratio of 0.05.
| Current Ratio | 0.08 |
| Quick Ratio | 0.05 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.86 |
Financial Efficiency
Return on equity (ROE) is -221.37% and return on invested capital (ROIC) is -11.05%.
| Return on Equity (ROE) | -221.37% |
| Return on Assets (ROA) | -7.41% |
| Return on Invested Capital (ROIC) | -11.05% |
| Return on Capital Employed (ROCE) | -143.24% |
| Revenue Per Employee | $244,750 |
| Profits Per Employee | -$10.17M |
| Employee Count | 5 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 1.31 |
Taxes
| Income Tax | -917,997 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -95.32% in the last 52 weeks. The beta is 3.42, so Onconetix's price volatility has been higher than the market average.
| Beta (5Y) | 3.42 |
| 52-Week Price Change | -95.32% |
| 50-Day Moving Average | 3.06 |
| 200-Day Moving Average | 5.83 |
| Relative Strength Index (RSI) | 46.24 |
| Average Volume (20 Days) | 30,968 |
Short Selling Information
The latest short interest is 63,863, so 4.09% of the outstanding shares have been sold short.
| Short Interest | 63,863 |
| Short Previous Month | 125,367 |
| Short % of Shares Out | 4.09% |
| Short % of Float | 5.08% |
| Short Ratio (days to cover) | 2.24 |
Income Statement
In the last 12 months, Onconetix had revenue of $1.22 million and -$50.85 million in losses. Loss per share was -$89.08.
| Revenue | 1.22M |
| Gross Profit | 1.05M |
| Operating Income | -4.84M |
| Pretax Income | -50.06M |
| Net Income | -50.85M |
| EBITDA | -4.70M |
| EBIT | -4.84M |
| Loss Per Share | -$89.08 |
Full Income StatementBalance Sheet
The company has $836,556 in cash and $166,422 in debt, giving a net cash position of $670,134 or $0.43 per share.
| Cash & Cash Equivalents | 836,556 |
| Total Debt | 166,422 |
| Net Cash | 670,134 |
| Net Cash Per Share | $0.43 |
| Equity (Book Value) | 3.37M |
| Book Value Per Share | 2.16 |
| Working Capital | -15.00M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.51 million and capital expenditures -$3,874, giving a free cash flow of -$7.51 million.
| Operating Cash Flow | -7.51M |
| Capital Expenditures | -3,874 |
| Free Cash Flow | -7.51M |
| FCF Per Share | -$4.81 |
Full Cash Flow StatementMargins
| Gross Margin | 85.41% |
| Operating Margin | -395.14% |
| Pretax Margin | -4,090.57% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Onconetix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -1,265.21% |
| FCF Yield | -186.86% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 13, 2025. It was a reverse split with a ratio of 1:85.
| Last Split Date | Jun 13, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:85 |
Scores
Onconetix has an Altman Z-Score of -11.12 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.12 |
| Piotroski F-Score | 3 |